Posts by Mary Krause

Progress toward an FTD cure depends on communities and researchers working together.

As 2025 comes to a close, we reflect on a year of growth and engagement that underscores the FTD Disorders Registry’s role in advancing research and amplifying the voices of those impacted by FTD.

The FTD Disorders Registry was featured at CTAD in San Diego, where a poster presented by Dr. Shana Dodge highlighted how the Registry is helping accelerate clinical trial recruitment in frontotemporal degeneration.

Every biosample holds valuable information that brings us closer to earlier diagnosis and effective treatments for FTD.

The Fall Research Roundup highlights new studies now enrolling people living with FTD, care partners, and biological family members.

Registry data is helping to bridge the gap between the FTD and ALS research communities and to accelerate recruitment for future clinical trials.

Registry data reveal which FTD subtypes and genes have the highest representation of research-ready participants, helping scientists design stronger, more focused studies.

Alector has announced topline results from its Phase 3 INFRONT-3 trial of latozinemab for FTD-GRN.

Progress is possible. See how Registry data can unlock breakthroughs in FTD research just as new treatments are showing progress in other neurological disorders.

Only a fraction of people with FTD and their relatives pursue genetic testing. This World FTD Awareness Week, discover how genetic counseling can guide the way.